BIRC5 promotes cancer progression and predicts prognosis in laryngeal squamous cell carcinoma

PeerJ. 2022 Feb 1:10:e12871. doi: 10.7717/peerj.12871. eCollection 2022.

Abstract

Background: Laryngeal squamous cell carcinoma (LSCC) remains one of the most common respiratory tumors worldwide. Baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5) is a member of the inhibitor-of-apoptosis protein family. BIRC5 plays an important role in various types of cell proliferation, differentiation, migration and invasion. However, the specific role of BIRC5 in LSCC remains unclear.

Methods: To provide a prognostic biomarker for LSCC, we screened the prognostic genes of LSCC via bioinformatics. PPI network and KEGG pathways were used to select hub genes. Clinical prognoses were performed using a Kaplan-Meier plotter and Cox proportional-hazard analysis. BIRC5 expression in LSCC tissues and cell lines were detected by RT-PCR, Western blot and Immunohistochemistry (IHC). Cell proliferation, cell cycle and cell apoptosis were detected with Cell Counting Kit-8 (CCK-8) and Flow Cytometry assay, respectively.

Results: Here, BIRC5 was strongly correlated with higher tumor grade and differentiation. BIRC5 was highly expressed in LSCC tissues when compared with normal tissues and increased expression of BIRC5 was associated with overall survival in LSCC patients. The suppression of BIRC5 induced cell apoptosis and cell cycle arrest, thereby inhibiting the proliferation of LSCC cells. The survival analysis confirmed that higher level of BIRC5 expression predicted poor prognosis of LSCC patients. BIRC5 may act as an oncogene of LSCC development and was suggested as a promising prognostic biomarker for LSCC.

Keywords: BIRC5; Bioinformatics; Cell apoptosis; Laryngeal squamous cell carcinoma; Prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Carcinoma, Squamous Cell* / genetics
  • Head and Neck Neoplasms*
  • Humans
  • Laryngeal Neoplasms* / genetics
  • Neoplastic Processes
  • Prognosis
  • Squamous Cell Carcinoma of Head and Neck / genetics
  • Survivin / genetics

Substances

  • Biomarkers
  • BIRC5 protein, human
  • Survivin

Grants and funding

The study was supported by the Natural Science Foundation of Guangdong Province (2021A1515011026), and the Natural Science Foundation of Jiaying University (2019KJZ01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.